Project Grant R35CA283998
Award Date
9/1/24
Completion Date
8/31/31
Dollars Obligated
$954K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the University of Pittsburgh provides $552,968.00 in funding from September 21, 2024 to March 31, 2027. The grant supports research focused on understanding the role of transfer RNA (tRNA) modifications in glioblastoma, an aggressive form of brain cancer. The principal investigator will use mass spectrometry and ribosome profiling techniques to study how metabolic changes and aberrant tRNA...
This $249,000 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research to decode the evolution and progression of glioma, an incurable brain cancer. The research aims to develop a multi-dimensional model of glioma progression by leveraging novel single-cell technologies to concurrently profile the transcriptome, epigenome, and genome of glioma cells. This will elucidate how somatic mutations and epigenetic changes...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $574,427 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the University of Pittsburgh to investigate the role of amino acid metabolism in regulating glioblastoma growth and immune interactions. The research aims to elucidate the molecular and cellular mechanisms by which selective amino acid catabolism in glioblastoma cells can promote tumor progression...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $682,596 in funding to The University of Texas Southwestern Medical Center to investigate the metabolic mechanisms underlying glioma progression. The award aims to: Dissect the molecular basis for metabolic reprogramming and aberrant metabolite secretion in high-grade gliomas. Determine the impact of aberrant metabolite secretion by glioma cells on excitability of the tumor...
The federal Project Grant award, provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), is supporting research at Case Western Reserve University (CWRU) to study translation regulation in glioblastoma stem-like cells (GSCs) and their adaptation to hypoxic tumor environments. The $107,948 award, effective January 9, 2025 through July 16, 2028, will employ ribosome profiling and RNA sequencing techniques to quantify the influence of hypoxia on translational...
The National Institute on Aging (CFDA 93.866 Aging Research) awarded a $388,750 Project Grant to The Washington University in St. Louis to conduct research on the role of senescent cancer-associated fibroblasts (sCAFs) in breast cancer progression. The researchers aim to determine how sCAFs impact extracellular matrix dynamics, tumor cell migration, and natural killer cell function to promote breast cancer growth and metastasis. The study will utilize state-of-the-art immunological and...
This Project Grant award of $445,996 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research to determine how mitigating oxidative stress at telomeres can improve T cell function in an adoptive cell therapy model for cancer treatment. The research aims to 1) mechanistically understand the role of oxidative damage at telomeres on T cell function and how protecting telomeres with an antioxidant scavenger can improve T cell anti-tumor activity in mouse...
This $680,334 Project Grant awarded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) supports research at the Icahn School of Medicine at Mount Sinai to elucidate the molecular mechanisms driving age-associated pro-tumoral myelopoiesis, a key factor contributing to increased cancer risk and progression in the elderly. The research aims to identify the specific cellular players and signaling pathways involved in the age-related inflammatory response, characterize the...
The National Cancer Institute (NCI) awarded a $447,831 Project Grant (CFDA 93.395 Cancer Treatment Research) to the University of Colorado-Denver to develop chimeric antigen receptor (CAR) phagocytes against glioblastoma, a type of brain cancer. The 5-year project, running from July 1, 2024 to June 30, 2029, aims to advance novel immunotherapy approaches for treating pediatric high-grade gliomas, which include glioblastoma, anaplastic astrocytoma, and diffuse intrinsic pontine glioma. This...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of a combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The $609,749 award to the University of North Carolina at Chapel Hill aims to: Develop an injectable, biodegradable hydrogel scaffold that can deliver high concentrations of induced neural stem cells (iNSCs) for...